It looks like it's a step in the right direction. There are several classes of insulin products available today: Rapid-acting insulin, short-acting ("normal i

It looks like it's a step in the right direction. There are several classes of insulin products available today: Rapid-acting insulin, short-acting ("normal insulin"), intermediate-acting, long-acting, ultra-long acting and pre-mixed (a combination of the above). Lantus, the first one mentioned in the article, is a long-acting insulin. Novolog, novolin, and levemir are rapid, sort/intermediate, and long respectively. So it's not just basic insulin that is seeing the price reduction.